Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HTD1801
- Development stage
- Unknown
- Lead developer
- HighTide Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HTD1801 is a first-in-class ionic salt of berberine and ursodeoxycholic acid (UDCA) being developed by HighTide Biopharma. This novel molecular entity is designed to address multiple metabolic and liver disorders simultaneously by leveraging the synergistic effects of its two active components. Berberine acts as a metabolic regulator that activates AMP-activated protein kinase (AMPK) and inhibits the expression of PCSK9, thereby lowering LDL cholesterol and improving glucose metabolism. Ursodeoxycholic acid is a hydrophilic bile acid that provides hepatoprotective effects, modulates the bile acid pool, and reduces liver inflammation. HTD1801 is currently under clinical investigation for the treatment of hypercholesterolemia, non-alcoholic steatohepatitis (NASH/MASH), primary sclerosing cholangitis (PSC), and type 2 diabetes.
- Other names
- berberine ursodeoxycholateberberine ursodeoxycholate saltberberine-UDCA salt
02
Targets
LDLR (Low-density lipoprotein receptor)AMPK (Adenosine monophosphate–activated protein kinase)PCSK9 (Proprotein convertase subtilisin/kexin type 9)GPBAR1
Beyond the preview
Go deeper on HTD1801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HTD1801.